癌症风险外显率Meta分析中确认偏倚的校正
针对ATM和PALB2等中等风险基因,病例对照研究估计的外显率常存在确认偏倚。该研究提出贝叶斯随机效应Meta分析方法,通过引入偏倚项和先验分布校正确认偏倚,模拟验证后应用于估计乳腺癌外显率,结果显示ATM和PALB2携带者的乳腺癌风险估计更准确。
要点
- 所提贝叶斯随机效应Meta分析可纳入存在确认偏倚的研究并校正偏倚。
- ATM携带者乳腺癌风险至50岁为5.77%,至80岁为26.13%。
- PALB2携带者乳腺癌风险至50岁为12.99%,至80岁为44.69%。
核心结论
- 所提方法允许Meta分析纳入存在确认偏倚的研究,从而纳入更多研究并获得更准确的外显率估计。
研究设计与样本
- 方法学研究:贝叶斯随机效应Meta分析,通过引入偏倚项和适当先验分布校正确认偏倚,并经模拟研究验证后应用于ATM和PALB2基因致病性变异携带者的乳腺癌外显率估计。
主要发现
- 模拟研究显示,与不校正确认偏倚或剔除有偏研究相比,所提方法的外显率估计更准确、更精确。
- ATM基因致病性变异携带者的乳腺癌风险至50岁为5.77%(3.22%-9.67%),至80岁为26.13%(20.31%-32.94%)。
- PALB2基因致病性变异携带者的乳腺癌风险至50岁为12.99%(6.48%-22.23%),至80岁为44.69%(34.40%-55.80%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multi-gene panel testing allows efficient detection of pathogenic variants in cancer susceptibility genes including moderate-risk genes such as ATM and PALB2. A growing number of studies examine the risk of breast cancer (BC) conferred by pathogenic variants of these genes. A meta-analysis combining the reported risk estimates can provide an overall estimate of age-specific risk of developing BC, that is, penetrance for a gene. However, estimates reported by case-control studies often suffer from ascertainment bias. Currently, there is no method available to adjust for such bias in this setting. We consider a Bayesian random effect meta-analysis method that can synthesize different types of risk measures and extend it to incorporate studies with ascertainment bias. This is achieved by introducing a bias term in the model and assigning appropriate priors. We validate the method through a simulation study and apply it to estimate BC penetrance for carriers of pathogenic variants in the ATM and PALB2 genes. Our simulations show that the proposed method results in more accurate and precise penetrance estimates compared to when no adjustment is made for ascertainment bias or when such biased studies are discarded from the analysis. The overall estimated BC risk for individuals with pathogenic variants are (1) 5.77% (3.22%-9.67%) by age 50 and 26.13% (20.31%-32.94%) by age 80 for ATM; (2) 12.99% (6.48%-22.23%) by age 50, and 44.69% (34.40%-55.80%) by age 80 for PALB2. The proposed method allows meta-analyses to include studies with ascertainment bias, resulting in inclusion of more studies and thereby more accurate estimates.
引用
- Ruberu TLM, Braun D, Parmigiani G, et al. Adjusting for Ascertainment Bias in Meta-Analysis of Penetrance for Cancer Risk. Stat Med. 2025. PMID: 39865362. doi:10.1002/sim.10323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。